Blackstone acquired Clarus in 2018, according to a LinkedIn post referencing the deal. The post did not disclose the amount paid.
The reference appears in a commentary post about a separate transaction involving Blackstone Life Sciences and Boston Scientific. The author notes that Nicholas Galakatos, Global Head of Blackstone Life Sciences, started at Venrock before founding MPM Capital and then Clarus Ventures, describing both firms as having brought large amounts of capital into life sciences. The post states that Blackstone acquired Clarus in 2018.
The post also says Blackstone Life Sciences closed on a $6.3 billion fund earlier this year, and that most of its investments have gone into biopharma.
No further details of the Clarus acquisition, including its terms, timing beyond the year given, or rationale, were provided in the source.